ERCC1 and lung adenocarcinoma: Novelty of the present study is that low ERCC1 expression is confirmed as a good predictive marker in all stages of lung adenocarcinoma in patients treated with platinum-based chemotherapy alone, or in combination with surgery or radiotherapy.